Drugs / BCG vaccine SSI
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04152161 | Oct 2019 → May 2024 | tuberculosis | Gates Medical Research Institute | Terminated | Missed primary Stop: Business |
| Phase 41 trial | ||||||
| Phase 4 | NCT05766345 | Oct 2023 → Aug 2024 | — | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02259608 | Nov 2013 → Mar 2014 | — | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG vaccine SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259608 ↗ |
| Known as | BCG-Vaccin SSI | “y-Irradiated BCG vaccine (BCG-Vaccin SSI” NCT02259608 ↗ |
| Modality | Vaccine | “γ-irradiated BCG vaccine” NCT02259608 ↗ |
| Route | Other | “administered intradermally in deltoid region of the upper arm” NCT04152161 ↗ |